Defence Therapeutics Completes 1st Tranche of Financing
Defence Therapeutics has completed the first tranche of its non-brokered private placement, raising $775,000 through the sale of units at $0.50 each. Each unit comprises one common share and half a warrant, with each whole warrant exercisable at $1.00 per share within 24 months. The company paid $14,000 in finder's fees and issued 28,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital. All securities are subject to a four-month hold period.
Defence Therapeutics ha completato la prima tranche della sua offerta privata non mediata, raccogliendo 775.000 dollari tramite la vendita di unità a 0,50 dollari ciascuna. Ogni unità è composta da un'azione comune e da mezzo warrant, con ogni warrant intero esercitabile a 1,00 dollaro per azione entro 24 mesi. L'azienda ha pagato 14.000 dollari come commissioni ai procacciatori e ha emesso 28.000 warrant per i procacciatori. I proventi sosterranno programmi preclinici e clinici e capitale circolante. Tutti i titoli sono soggetti a un periodo di blocco di quattro mesi.
Defence Therapeutics ha completado la primera tranche de su colocación privada no intermediada, recaudando 775,000 dólares a través de la venta de unidades a 0.50 dólares cada una. Cada unidad consiste en una acción común y medio warrant, siendo ejercitable cada warrant completo a 1.00 dólar por acción dentro de 24 meses. La compañía pagó 14,000 dólares en comisiones a intermediarios y emitió 28,000 warrants para intermediarios. Los fondos se destinarán a programas preclínicos y clínicos, así como a capital de trabajo. Todos los valores están sujetos a un período de bloqueo de cuatro meses.
Defence Therapeutics는 중개인이 없는 사모 유상증자 첫 번째 트랜치를 완료하며 775,000달러를 모집하였습니다. 유닛 당 0.50달러에 판매되며, 각 유닛은 하나의 보통주와 반개의 워런트로 구성됩니다. 각 전체 워런트는 24개월 이내에 주당 1.00달러에 행사할 수 있습니다. 회사는 14,000달러의 중개수수료를 지급하고 28,000개의 중개인 워런트를 발행하였습니다. 이러한 자금은 임상 전 및 임상 프로그램과 운영 자본을 지원하는 데 사용될 것입니다. 모든 증권은 4개월의 보유 기간에 적용됩니다.
Defence Therapeutics a complété la première tranche de son placement privé sans courtier, levant 775 000 dollars grâce à la vente d'unités à 0,50 dollars chacune. Chaque unité comprend une action ordinaire et la moitié d'un bon de souscription, chaque bon de souscription entier pouvant être exercé à 1,00 dollar par action dans les 24 mois. La société a payé 14 000 dollars en frais de recherche et a émis 28 000 bons de souscription pour les chercheurs. Les fonds serviront à soutenir des programmes précliniques et cliniques ainsi qu'à des besoins en fonds de roulement. Tous les titres sont soumis à une période de blocage de quatre mois.
Defence Therapeutics hat die erste Tranche seiner nicht vermittelten Privatplatzierung abgeschlossen und dabei 775.000 US-Dollar durch den Verkauf von Einheiten zu je 0,50 US-Dollar eingesammelt. Jede Einheit besteht aus einer Stammaktie und einem halben Warrant, wobei jeder ganze Warrant innerhalb von 24 Monaten zu einem Preis von 1,00 US-Dollar pro Aktie ausgeübt werden kann. Das Unternehmen zahlte 14.000 US-Dollar an Vermittlungsgebühren und gab 28.000 Vermittlungs-Warrants aus. Die Erlöse sollen präklnische und klinische Programme sowie Betriebskapital unterstützen. Alle Wertpapiere unterliegen einer viermonatigen Haltefrist.
- Successfully raised $775,000 in new capital
- Warrants priced at $1.00 represent 100% premium to unit price
- Share dilution through new unit issuance
- Additional dilution possible through warrant exercise
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of the 1st tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of
In connection with the Closing, the Company paid a cash finder's fee of
The Company intends to use the net proceeds of the Offering to advance its preclinical and clinical programs and for general working capital. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.
The securities being referred to in this news release have not been, nor will they be, registered under the United States (U.S.) Securities Act of 1933, as amended, and may not be offered or sold in the U.S. or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Such forward-looking statements include, but are not limited to, the Company's intended use of proceeds of the Offering. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228411
FAQ
How much did Defence Therapeutics (DTCFF) raise in its first tranche of private placement?
What is the exercise price of warrants in Defence Therapeutics' (DTCFF) October 2024 private placement?
What will Defence Therapeutics (DTCFF) use the private placement proceeds for?
